Table 1. Lymphoma numbers and median ages (IQR) at diagnosis: Haematological Malignancy Research Network (HMRN) 2004–2012.
|
Total diagnoses |
Males |
Females |
|||||
|---|---|---|---|---|---|---|---|
| No (%) | Median age (IQR) | No (%) | Median age (IQR) | No (%) | Median age (IQR) | P Median age difference (male versus female) | |
| All lymphomas | 5796 (100) | 67.2 (54.9–76.5) | 3086 (100) | 66.0 (53.1–75.4) | 2710 (100) | 68.8 (56.7–77.7) | 0.001 |
| Non-Hodgkin | 4961 (85.6) | 69.1 (58.9–77.6) | 2614 (84.7) | 67.9 (57.9–76.5) | 2347 (86.6) | 70.5 (60.7–78.5) | 0.001 |
| Hodgkin | 835 (14.4) | 41.3 (26.8–63.5) | 472 (15.3) | 42.0 (27.7–61.5) | 363 (13.4) | 39.6 (26.0–65.8) | 0.358 |
| B-cell | 5488 (94.7) | 67.4 (55.1–76.6) | 2914 (94.4) | 66.1 (53.4–75.5) | 2574 (95.0) | 68.9 (56.9–77.7) | 0.001 |
| DLBCL | 2373 (40.9) | 70.0 (59.6–78.2) | 1243 (40.3) | 68.4 (58.0–76.9) | 1130 (41.7) | 71.4 (61.4–79.6) | 0.001 |
| DLBCL, NOS | 2312 (39.9) | 70.0 (59.7–78.2) | 1208 (39.1) | 68.4 (58.4–77.0) | 1104 (40.7) | 71.4 (61.3–79.5) | 0.001 |
| T-cell/histiocyte-rich | 32 (0.6) | 65.5 (52.7–77.3) | 17 (0.6) | 59.8 (44.1–74.4) | 15 (0.6) | 71.3 (61.5–78.9) | 0.188 |
| Plasmablastic | 24 (0.4) | 70.9 (54.4–78.2) | 15 (0.5) | 69.2 (53.4–75.1) | 9 (0.3) | 76.0 (68.4–81.5) | 0.482 |
| MZL | 983 (17.0) | 72.4 (63.8–79.2) | 537 (17.4) | 71.2 (63.5–78.6) | 446 (16.5) | 73.4 (64.1–79.5) | 0.021 |
| Systemic MZL | 772 (13.3) | 72.9 (65.3–79.4) | 434 (14.1) | 72.2 (64.6–79.2) | 338 (12.5) | 73.7 (66.2–79.8) | 0.117 |
| Extranodal MZL | 211 (3.6) | 68.8 (57.2–77.8) | 103 (3.3) | 66.5 (55.8–76.9) | 108 (4.0) | 72.4 (57.9–79.4) | 0.017 |
| FL | 923 (15.9) | 64.9 (55.8–73.3) | 412 (13.4) | 63.1 (55.0–72.8) | 511 (18.9) | 66.3 (56.5–73.8) | 0.001 |
| Follicular | 897 (15.5) | 65.0 (55.9–73.3) | 397 (12.9) | 63.2 (55.4–72.8) | 500 (18.5) | 66.4 (56.6–73.8) | 0.001 |
| Follicular, large cell | 26 (0.4) | 58.5 (50.0–71.9) | 15 (0.5) | 59.6 (44.4–74.9) | 11 (0.4) | 57.4 (52.2–71.3) | 0.805 |
| MCL | 247 (4.3) | 73.5 (64.3–80.3) | 159 (5.2) | 71.0 (61.2–78.9) | 88 (3.2) | 75.8 (67.3–82.6) | 0.006 |
| BL | 103 (1.8) | 52.2 (16.9–64.8) | 76 (2.5) | 39.4 (12.1–63.9) | 27 (1.0) | 56.8 (38.9–69.2) | 0.026 |
| Intermediate DLBCL/CHLa | 24 (0.4) | 59.3 (34.2–72.1) | 15 (0.5) | 54.5 (26.2–66.0) | 9 (0.3) | 71.8 (55.8–77.9) | 0.212 |
| CHL | 737 (12.7) | 40.9 (26.3–64.1) | 400 (13.0) | 42.0 (27.3–62.8) | 337 (12.4) | 38.1 (25.7–65.6) | 0.144 |
| Nodular sclerosis CHL | 545 (9.4) | 37.0 (25.0–59.4) | 283 (9.2) | 39.5 (25.6–59.4) | 262 (9.7) | 33.9 (24.5–59.5) | 0.006 |
| Mixed cellularity CHL | 173 (3.0) | 59.2 (36.1–70.6) | 102 (3.3) | 53.2 (34.3–69.2) | 71 (2.6) | 65.4 (40.5–72.5) | 0.004 |
| Lymphocyte-rich CHL | 18 (0.3) | 49.3 (35.9–59.7) | 14 (0.5) | 47.8 (34.5–57.7) | 4 (0.1) | 59.4 (51.5–61.9) | 0.195 |
| Lymphocyte predominant nodular HL | 98 (1.7) | 43.6 (29.9–59.1) | 72 (2.3) | 41.6 (30.3–55.7) | 26 (1.0) | 55.2 (27.2–65.9) | 0.096 |
| T-cell | 308 (5.3) | 65.1 (51.8–74.8) | 172 (5.6) | 63.9 (49.1–73.6) | 136 (5.0) | 68.3 (54.4–76.6) | 0.070 |
| Peripheral—common, unspecified | 91 (1.6) | 68.5 (52.9–77.2) | 57 (1.8) | 65.9 (49.8–73.9) | 34 (1.3) | 71.6 (59.1–81.7) | 0.295 |
| Angioimmunoblastic | 55 (0.9) | 71.9 (61.6–78.4) | 20 (0.6) | 67.7 (55.2–75.9) | 35 (1.3) | 72.9 (64.6–80.1) | 0.281 |
| Anaplastic large cell | 46 (0.8) | 59.2 (41.3–74.3) | 28 (0.9) | 54.0 (40.1–73.4) | 18 (0.7) | 63.5 (43.2–75.7) | 0.334 |
| ALK-negative | 27 (0.5) | 69.0 (57.4–81.6) | 15 (0.5) | 72.4 (61.0–77.6) | 12 (0.4) | 64.4 (54.4–86.5) | 0.407 |
| ALK-positive | 16 (0.3) | 35.6 (24.3–43.9) | 12 (0.4) | 39.7 (27.3–44.4) | 4 (0.1) | 25.5 (15.3–36.6) | 0.275 |
| Mycosis fungoides | 39 (0.7) | 65.8 (53.9–75.8) | 28 (0.9) | 67.0 (53.8–76.0) | 11 (0.4) | 63.0 (54.8–70.6) | 0.513 |
| Primary cutaneous CD30+ LPD | 37 (0.6) | 52.9 (39.4–70.5) | 19 (0.6) | 61.5 (39.0–73.1) | 18 (0.7) | 49.3 (39.4–62.6) | 0.233 |
| Enteropathy-type | 24 (0.4) | 62.7 (58.6–68.1) | 13 (0.4) | 61.6 (58.0–64.0) | 11 (0.4) | 65.0 (60.6–71.4) | 0.343 |
Abbreviations: ALK=anaplastic lymphoma kinase; BL=Burkitt lymphoma; CHL=classical Hodgkin lymphoma; DLBCL=diffuse large B-cell lymphoma; FL=follicular lymphoma; IQR=interquartile range; LPD=lymphoproliferative disorders; MCL=mantle cell lymphoma; MZL=marginal zone lymphoma; NOS=not otherwise specified.
a
Cases classified 2009–2012 only.